ReP USP - Resultado da busca

Artigo de periodico
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 (2021)
Lawler, Patrick R; Golighe, Ewan C; Berge, Jeffrey S; Neal, Matthew D; Mcverry, Bryan J; Nicolau, Jose Carlos ; Gong, Michelle N; Carrier, Marc; Rosenson, Robert S; Reynolds, Harmony R
Source: New england journal of medicine. Unidade: FM
Subjects: COVID-19, TROMBOSE, ANTICOAGULANTES, PREVENÇÃO DE DOENÇA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LAWLER, Patrick R et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New england journal of medicine, v. 385, n. 9, p. 790-802, 2021Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa2105911. Acesso em: 03 jun. 2024.
APA
Lawler, P. R., Golighe, E. C., Berge, J. S., Neal, M. D., Mcverry, B. J., Nicolau, J. C., et al. (2021). Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New england journal of medicine, 385( 9), 790-802. doi:10.1056/NEJMoa2105911
NLM
Lawler PR, Golighe EC, Berge JS, Neal MD, Mcverry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 790-802.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1056/NEJMoa2105911
Vancouver
Lawler PR, Golighe EC, Berge JS, Neal MD, Mcverry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 790-802.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1056/NEJMoa2105911
Artigo de periodico
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 (2021)
Goligher, Ewan C; Bradbury, Charlotte A; Mcverry, Bryan J; Lawler, Patrick R; Berger, Jeffrey S; Gong, Michelle N; Carrier, Marc; Reynolds, Harmony R; Kumar, Anand; Nicolau, Jose Carlos
Source: New england journal of medicine. Unidade: FM
Subjects: COVID-19, TROMBOSE, ANTICOAGULANTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GOLIGHER, Ewan C et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New england journal of medicine, v. 385, n. 9, p. 777-789, 2021Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa2103417. Acesso em: 03 jun. 2024.
APA
Goligher, E. C., Bradbury, C. A., Mcverry, B. J., Lawler, P. R., Berger, J. S., Gong, M. N., et al. (2021). Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New england journal of medicine, 385( 9), 777-789. doi:10.1056/NEJMoa2103417
NLM
Goligher EC, Bradbury CA, Mcverry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Nicolau JC. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 777-789.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1056/NEJMoa2103417
Vancouver
Goligher EC, Bradbury CA, Mcverry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Nicolau JC. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 777-789.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1056/NEJMoa2103417
Artigo de periodico
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes (2020)
Petrie, Mark C; Verma, Subodh; Docherty, Kieran F; Inzucchi, Silvio E; Anand, Inder; Belohlavek, Jan; Boehm, Michael; Chiang, Chern-En; Chopra, Vijay K.; Nicolau, José Carlos
Source: Jama-journal of the american medical association. Unidade: FM
Subjects: DIABETES MELLITUS, MÉTODO DUPLO-CEGO, HEMOGLOBINAS, INSUFICIÊNCIA CARDÍACA, FÁRMACOS (METABOLISMO E NUTRIÇÃO), PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PETRIE, Mark C et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Jama-journal of the american medical association, v. 323, n. 14, p. 1353-1368, 2020Tradução . . Disponível em: https://doi.org/10.1001/jama.2020.1906. Acesso em: 03 jun. 2024.
APA
Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlavek, J., et al. (2020). Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Jama-journal of the american medical association, 323( 14), 1353-1368. doi:10.1001/jama.2020.1906
NLM
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, Boehm M, Chiang C-E, Chopra VK, Nicolau JC. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes [Internet]. Jama-journal of the american medical association. 2020 ; 323( 14): 1353-1368.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1001/jama.2020.1906
Vancouver
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, Boehm M, Chiang C-E, Chopra VK, Nicolau JC. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes [Internet]. Jama-journal of the american medical association. 2020 ; 323( 14): 1353-1368.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1001/jama.2020.1906
Artigo de periodico
Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial (2020)
Nicolau, José Carlos ; Bhatt, Deepak L; Hohnloser, Stefan H; Kimura, Takeshi; Lip, Gregory Y. H; Miede, Corinna; Nordaby, Matias; Oldgren, Jonas; Steg, Philippe Gabriel; Berg, Jurrien M. ten
Source: Drugs. Unidade: FM
Subjects: ANTICOAGULANTES, ESTUDOS PROSPECTIVOS, FIBRILAÇÃO ATRIAL, QUIMIOTERAPIA COMBINADA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NICOLAU, José Carlos et al. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial. Drugs, v. 80, n. 10, p. 995-1005, 2020Tradução . . Disponível em: https://doi.org/10.1007/s40265-020-01323-x. Acesso em: 03 jun. 2024.
APA
Nicolau, J. C., Bhatt, D. L., Hohnloser, S. H., Kimura, T., Lip, G. Y. H., Miede, C., et al. (2020). Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial. Drugs, 80( 10), 995-1005. doi:10.1007/s40265-020-01323-x
NLM
Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Berg JM ten. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial [Internet]. Drugs. 2020 ; 80( 10): 995-1005.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1007/s40265-020-01323-x
Vancouver
Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Berg JM ten. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial [Internet]. Drugs. 2020 ; 80( 10): 995-1005.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1007/s40265-020-01323-x
Artigo de periodico
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: a Prospective Interventional Trial (2020)
Arantes, Flavia B. B; Menezes, Fernando R; Franci, Andre; Barbosa, Carlos J. D. G; Dalcoquio, Talia F; Nakashima, Carlos A. K; Baracioli, Luciano M; Ramires, José Antônio Franchini ; Kalil Filho, Roberto ; Nicolau, José Carlos
Source: Advances in therapy. Unidade: FM
Subjects: ENVELHECIMENTO, AGREGAÇÃO PLAQUETÁRIA, ESTUDOS PROSPECTIVOS, MEIA IDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ARANTES, Flavia B. B et al. Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: a Prospective Interventional Trial. Advances in therapy, v. 37, n. 1, p. 420-430, 2020Tradução . . Disponível em: https://doi.org/10.1007/s12325-019-01153-8. Acesso em: 03 jun. 2024.
APA
Arantes, F. B. B., Menezes, F. R., Franci, A., Barbosa, C. J. D. G., Dalcoquio, T. F., Nakashima, C. A. K., et al. (2020). Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: a Prospective Interventional Trial. Advances in therapy, 37( 1), 420-430. doi:10.1007/s12325-019-01153-8
NLM
Arantes FBB, Menezes FR, Franci A, Barbosa CJDG, Dalcoquio TF, Nakashima CAK, Baracioli LM, Ramires JAF, Kalil Filho R, Nicolau JC. Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: a Prospective Interventional Trial [Internet]. Advances in therapy. 2020 ; 37( 1): 420-430.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1007/s12325-019-01153-8
Vancouver
Arantes FBB, Menezes FR, Franci A, Barbosa CJDG, Dalcoquio TF, Nakashima CAK, Baracioli LM, Ramires JAF, Kalil Filho R, Nicolau JC. Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: a Prospective Interventional Trial [Internet]. Advances in therapy. 2020 ; 37( 1): 420-430.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1007/s12325-019-01153-8
Artigo de periodico
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial (2020)
Kosiborod, Mikhail N ; Jhund, Pardeep S; Docherty, Kieran F; Diez, Mirta; Petrie, Mark C; Verma, Subodh; Nicolau, Jose Carlos ; Merkely, Bela; Kitakaze, Masafumi; Demets, David L
Source: Circulation. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, QUALIDADE DE VIDA, BIOMARCADORES, HIDROCARBONOS AROMÁTICOS, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KOSIBOROD, Mikhail N et al. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial. Circulation, v. 141, n. 2, p. 90-99, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.044138. Acesso em: 03 jun. 2024.
APA
Kosiborod, M. N., Jhund, P. S., Docherty, K. F., Diez, M., Petrie, M. C., Verma, S., et al. (2020). Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial. Circulation, 141( 2), 90-99. doi:10.1161/CIRCULATIONAHA.119.044138
NLM
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, Demets DL. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial [Internet]. Circulation. 2020 ; 141( 2): 90-99.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Vancouver
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, Demets DL. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial [Internet]. Circulation. 2020 ; 141( 2): 90-99.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Artigo de periodico
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF (2020)
Martinez, Felipe A; Serenelli, Matteo; Nicolau, Jose Carlos ; Petrie, Mark C; Chiang, Chern-En; Tereshchenko, Sergey; Solomon, Scott D; Inzucchi, Silvio E; Kober, Lars; Kosiborod, Mikhail N
Source: Circulation. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, HIDROCARBONOS AROMÁTICOS, FATORES ETÁRIOS, RESULTADO DE TRATAMENTO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARTINEZ, Felipe A et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF. Circulation, v. 141, n. 2, p. 100-111, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.044133. Acesso em: 03 jun. 2024.
APA
Martinez, F. A., Serenelli, M., Nicolau, J. C., Petrie, M. C., Chiang, C. -E., Tereshchenko, S., et al. (2020). Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF. Circulation, 141( 2), 100-111. doi:10.1161/CIRCULATIONAHA.119.044133
NLM
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF [Internet]. Circulation. 2020 ; 141( 2): 100-111.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044133
Vancouver
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF [Internet]. Circulation. 2020 ; 141( 2): 100-111.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044133
Artigo de periodico
Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry (2020)
Pocock, Stuart J; Brieger, David; Gregson, John; Chen, Ji Y; Cohen, Mauricio G; Goodman, Shaun G; Granger, Christopher B; Grieve, Richard; Nicolau, José Carlos ; Simon, Tabassome
Source: Clinical cardiology. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, DOENÇAS CARDIOVASCULARES, FATORES DE RISCO, INCIDÊNCIA, ANÁLISE DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
POCOCK, Stuart J et al. Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. Clinical cardiology, v. 43, n. 1, p. 24-32, 2020Tradução . . Disponível em: https://doi.org/10.1002/clc.23283. Acesso em: 03 jun. 2024.
APA
Pocock, S. J., Brieger, D., Gregson, J., Chen, J. Y., Cohen, M. G., Goodman, S. G., et al. (2020). Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. Clinical cardiology, 43( 1), 24-32. doi:10.1002/clc.23283
NLM
Pocock SJ, Brieger D, Gregson J, Chen JY, Cohen MG, Goodman SG, Granger CB, Grieve R, Nicolau JC, Simon T. Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry [Internet]. Clinical cardiology. 2020 ; 43( 1): 24-32.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1002/clc.23283
Vancouver
Pocock SJ, Brieger D, Gregson J, Chen JY, Cohen MG, Goodman SG, Granger CB, Grieve R, Nicolau JC, Simon T. Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry [Internet]. Clinical cardiology. 2020 ; 43( 1): 24-32.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1002/clc.23283
Artigo de periodico
Relation of high lipoprotein (a) concentrations to platelet reactivity in Individuals with and without coronary artery disease (2020)
Salsoso, Rocío ; Dalçoquio, Talia Falcão; Furtado, Remo Holanda de Mendonça; Franci, André; Barbosa, Carlos José Dornas Gonçalves; Genestreti, Paulo Roberto Rizzo; Strunz, Célia Maria Cassaro; Lima, Viviane; Baracioli, Luciano Moreira; Giugliano, Robert P; Goodman, Shaun G; Gurbel, Paul A; Maranhão, Raul Cavalcante ; Nicolau, José Carlos
Source: Advances in Therapy. Unidades: FM, FCF
Subjects: LIPOPROTEÍNAS, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SALSOSO, Rocío et al. Relation of high lipoprotein (a) concentrations to platelet reactivity in Individuals with and without coronary artery disease. Advances in Therapy, v. 37, p. 4568–4584, 2020Tradução . . Disponível em: https://doi.org/10.1007/s12325-020-01483-y. Acesso em: 03 jun. 2024.
APA
Salsoso, R., Dalçoquio, T. F., Furtado, R. H. de M., Franci, A., Barbosa, C. J. D. G., Genestreti, P. R. R., et al. (2020). Relation of high lipoprotein (a) concentrations to platelet reactivity in Individuals with and without coronary artery disease. Advances in Therapy, 37, 4568–4584. doi:10.1007/s12325-020-01483-y
NLM
Salsoso R, Dalçoquio TF, Furtado RH de M, Franci A, Barbosa CJDG, Genestreti PRR, Strunz CMC, Lima V, Baracioli LM, Giugliano RP, Goodman SG, Gurbel PA, Maranhão RC, Nicolau JC. Relation of high lipoprotein (a) concentrations to platelet reactivity in Individuals with and without coronary artery disease [Internet]. Advances in Therapy. 2020 ; 37 4568–4584.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1007/s12325-020-01483-y
Vancouver
Salsoso R, Dalçoquio TF, Furtado RH de M, Franci A, Barbosa CJDG, Genestreti PRR, Strunz CMC, Lima V, Baracioli LM, Giugliano RP, Goodman SG, Gurbel PA, Maranhão RC, Nicolau JC. Relation of high lipoprotein (a) concentrations to platelet reactivity in Individuals with and without coronary artery disease [Internet]. Advances in Therapy. 2020 ; 37 4568–4584.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1007/s12325-020-01483-y
Artigo de periodico
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54 (2020)
Furtado, Remo H. M; Nicolau, José Carlos ; Magnani, Giulia; Im, Kyungah; Bhatt, Deepak L; Storey, Robert F; Steg, P. Gabriel; Spinar, Jindrich; Budaj, Andrzej; Kontny, Frederic
Source: European heart journal. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, TERAPÊUTICA, RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M et al. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European heart journal, v. 41, n. 17, p. 1625-+, 2020Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehz821. Acesso em: 03 jun. 2024.
APA
Furtado, R. H. M., Nicolau, J. C., Magnani, G., Im, K., Bhatt, D. L., Storey, R. F., et al. (2020). Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European heart journal, 41( 17), 1625-+. doi:10.1093/eurheartj/ehz821
NLM
Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54 [Internet]. European heart journal. 2020 ; 41( 17): 1625-+.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1093/eurheartj/ehz821
Vancouver
Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54 [Internet]. European heart journal. 2020 ; 41( 17): 1625-+.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1093/eurheartj/ehz821
Artigo de periodico
Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries (2020)
Brieger, David; Pocockb, Stuart J; Blankenberg, Stefan; Chen, Ji Yan; Cohen, Mauricio G; Granger, Christopher B; Grieve, Richard; Nicolau, Jose Carlos ; Simon, Tabassome; Westermann, Dirk
Source: International journal of cardiology. Unidade: FM
Subjects: ENVELHECIMENTO, INFARTO DO MIOCÁRDIO, FATORES DE RISCO, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRIEGER, David et al. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. International journal of cardiology, v. 311, p. 7-14, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.ijcard.2020.01.070. Acesso em: 03 jun. 2024.
APA
Brieger, D., Pocockb, S. J., Blankenberg, S., Chen, J. Y., Cohen, M. G., Granger, C. B., et al. (2020). Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. International journal of cardiology, 311, 7-14. doi:10.1016/j.ijcard.2020.01.070
NLM
Brieger D, Pocockb SJ, Blankenberg S, Chen JY, Cohen MG, Granger CB, Grieve R, Nicolau JC, Simon T, Westermann D. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries [Internet]. International journal of cardiology. 2020 ; 311 7-14.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1016/j.ijcard.2020.01.070
Vancouver
Brieger D, Pocockb SJ, Blankenberg S, Chen JY, Cohen MG, Granger CB, Grieve R, Nicolau JC, Simon T, Westermann D. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries [Internet]. International journal of cardiology. 2020 ; 311 7-14.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1016/j.ijcard.2020.01.070
Artigo de periodico
Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial (2020)
Houston, Brett L; Lawler, Patrick R; Goligher, Ewan C; Farkouh, Michael E; Bradbury, Charlotte; Carrier, Marc; Dzavik, Vlad; Fergusson, Dean A; Fowler, Robert A; Nicolau, Jose Carlos
Source: Clinical trials. Unidade: FM
Subjects: ADULTOS, ANTICOAGULANTES, TROMBOSE, RESULTADO DE TRATAMENTO, PANDEMIAS, COVID-19
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HOUSTON, Brett L et al. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clinical trials, v. 17, n. 5, p. 491-500, 2020Tradução . . Disponível em: https://doi.org/10.1177/1740774520943846. Acesso em: 03 jun. 2024.
APA
Houston, B. L., Lawler, P. R., Goligher, E. C., Farkouh, M. E., Bradbury, C., Carrier, M., et al. (2020). Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clinical trials, 17( 5), 491-500. doi:10.1177/1740774520943846
NLM
Houston BL, Lawler PR, Goligher EC, Farkouh ME, Bradbury C, Carrier M, Dzavik V, Fergusson DA, Fowler RA, Nicolau JC. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial [Internet]. Clinical trials. 2020 ; 17( 5): 491-500.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1177/1740774520943846
Vancouver
Houston BL, Lawler PR, Goligher EC, Farkouh ME, Bradbury C, Carrier M, Dzavik V, Fergusson DA, Fowler RA, Nicolau JC. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial [Internet]. Clinical trials. 2020 ; 17( 5): 491-500.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1177/1740774520943846
Artigo de periodico
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial (2020)
Furtado, Remo H. M; Venkateswaran, Ramkumar V; Nicolau, José Carlos ; Gurmu, Yared; Bhatt, Deepak L; Storey, Robert F; Steg, P. Gabriel; Magnani, Giuglia; Goto, Shinya; Dellborg, Mikael
Source: Journal of the american heart association. Unidade: FM
Subjects: CAFEÍNA, DISPNEIA, MORTALIDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M et al. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial. Journal of the american heart association, v. 9, n. 10, 2020Tradução . . Disponível em: https://doi.org/10.1161/JAHA.119.015785. Acesso em: 03 jun. 2024.
APA
Furtado, R. H. M., Venkateswaran, R. V., Nicolau, J. C., Gurmu, Y., Bhatt, D. L., Storey, R. F., et al. (2020). Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial. Journal of the american heart association, 9( 10). doi:10.1161/JAHA.119.015785
NLM
Furtado RHM, Venkateswaran RV, Nicolau JC, Gurmu Y, Bhatt DL, Storey RF, Steg PG, Magnani G, Goto S, Dellborg M. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial [Internet]. Journal of the american heart association. 2020 ; 9( 10):[citado 2024 jun. 03 ] Available from: https://doi.org/10.1161/JAHA.119.015785
Vancouver
Furtado RHM, Venkateswaran RV, Nicolau JC, Gurmu Y, Bhatt DL, Storey RF, Steg PG, Magnani G, Goto S, Dellborg M. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial [Internet]. Journal of the american heart association. 2020 ; 9( 10):[citado 2024 jun. 03 ] Available from: https://doi.org/10.1161/JAHA.119.015785
Artigo de periodico
Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF (2020)
Docherty, Kieran F; Jhund, Pardeep S; Anand, Inder; Bengtsson, Olof; Bohm, Michael; Boer, Rudolf A. de; Demets, David L; Desai, Akshay S; Drozdz, Jaroslaw; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: ENVELHECIMENTO, MÉTODO DUPLO-CEGO, INSUFICIÊNCIA CARDÍACA, PACIENTES AMBULATORIAIS, ESTUDOS RETROSPECTIVOS, HEMODINÂMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOCHERTY, Kieran F et al. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF. Circulation, v. 142, n. 17, p. 1623-1632, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.120.047480. Acesso em: 03 jun. 2024.
APA
Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Bohm, M., Boer, R. A. de, et al. (2020). Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF. Circulation, 142( 17), 1623-1632. doi:10.1161/CIRCULATIONAHA.120.047480
NLM
Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, Boer RA de, Demets DL, Desai AS, Drozdz J, Nicolau JC. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF [Internet]. Circulation. 2020 ; 142( 17): 1623-1632.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047480
Vancouver
Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, Boer RA de, Demets DL, Desai AS, Drozdz J, Nicolau JC. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF [Internet]. Circulation. 2020 ; 142( 17): 1623-1632.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047480
Artigo de periodico
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome (2020)
Bittner, Vera A; Szarek, Michael; Aylward, Philip E; Bhatt, Deepak L; Diaz, Rafael; Edelberg, Jay M; Fras, Zlatko; Goodman, Shaun G; Halvorsen, Sigrun; Nicolau, José Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, LIPOPROTEÍNAS, ENZIMAS PROTEOLÍTICAS, LIPOPROTEÍNAS LDL, ESTATINAS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BITTNER, Vera A et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the american college of cardiology, v. 75, n. 2, p. 133-144, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.10.057. Acesso em: 03 jun. 2024.
APA
Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., et al. (2020). Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the american college of cardiology, 75( 2), 133-144. doi:10.1016/j.jacc.2019.10.057
NLM
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Nicolau JC. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome [Internet]. Journal of the american college of cardiology. 2020 ; 75( 2): 133-144.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1016/j.jacc.2019.10.057
Vancouver
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Nicolau JC. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome [Internet]. Journal of the american college of cardiology. 2020 ; 75( 2): 133-144.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1016/j.jacc.2019.10.057
Artigo de periodico
Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography (2020)
Furtado, Remo H. M; Nicolau, José Carlos ; Guo, Jianping; Im, Kyungah; White, Jennifer A; Sabatine, Marc S; Newby, L. Kristin; Giugliano, Robert P
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, MORFINA, ANGIOGRAFIA, DOENÇAS CARDIOVASCULARES, AGREGAÇÃO PLAQUETÁRIA, INTERAÇÃO DE MEDICAMENTOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M et al. Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. Journal of the american college of cardiology, v. 75, n. 3, p. 289-300, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.11.035. Acesso em: 03 jun. 2024.
APA
Furtado, R. H. M., Nicolau, J. C., Guo, J., Im, K., White, J. A., Sabatine, M. S., et al. (2020). Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. Journal of the american college of cardiology, 75( 3), 289-300. doi:10.1016/j.jacc.2019.11.035
NLM
Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, Newby LK, Giugliano RP. Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography [Internet]. Journal of the american college of cardiology. 2020 ; 75( 3): 289-300.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1016/j.jacc.2019.11.035
Vancouver
Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, Newby LK, Giugliano RP. Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography [Internet]. Journal of the american college of cardiology. 2020 ; 75( 3): 289-300.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1016/j.jacc.2019.11.035
Artigo de periodico
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery (2019)
Goodman, Shaun G; Aylward, Philip E; Szarek, Michael; Chumburidze, Vakhtang; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Edelberg, Jay M; Hanotin, Corinne; Nicolau, José Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DOENÇAS CARDIOVASCULARES, REVASCULARIZAÇÃO MIOCÁRDICA, COMPLICAÇÕES PÓS-OPERATÓRIAS, ANTICORPOS MONOCLONAIS, ENZIMAS PROTEOLÍTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GOODMAN, Shaun G et al. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the american college of cardiology, v. 74, n. 9, p. 1177-1186, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.07.015. Acesso em: 03 jun. 2024.
APA
Goodman, S. G., Aylward, P. E., Szarek, M., Chumburidze, V., Bhatt, D. L., Bittner, V. A., et al. (2019). Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the american college of cardiology, 74( 9), 1177-1186. doi:10.1016/j.jacc.2019.07.015
NLM
Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Nicolau JC. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery [Internet]. Journal of the american college of cardiology. 2019 ; 74( 9): 1177-1186.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1016/j.jacc.2019.07.015
Vancouver
Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Nicolau JC. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery [Internet]. Journal of the american college of cardiology. 2019 ; 74( 9): 1177-1186.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1016/j.jacc.2019.07.015
Artigo de periodico-carta/editorial
Hydrophilic-coating material guidewire embolization after complex percutaneous coronary intervention: necroscopic findings (2019)
Lemos, Stefano G. D; Benvenuti, Luiz A; Aiello, Vera D; Nicolau, José Carlos ; Ribeiro, Expedito E; Ribeiro, Henrique B
Source: Coronary artery disease. Unidade: FM
Subjects: PROCEDIMENTOS CIRÚRGICOS CARDIOVASCULARES, EMBOLIZAÇÃO TERAPÊUTICA, SÍNDROME CORONARIANA AGUDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LEMOS, Stefano G. D et al. Hydrophilic-coating material guidewire embolization after complex percutaneous coronary intervention: necroscopic findings. Coronary artery disease. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1097/MCA.0000000000000681. Acesso em: 03 jun. 2024. , 2019
APA
Lemos, S. G. D., Benvenuti, L. A., Aiello, V. D., Nicolau, J. C., Ribeiro, E. E., & Ribeiro, H. B. (2019). Hydrophilic-coating material guidewire embolization after complex percutaneous coronary intervention: necroscopic findings. Coronary artery disease. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. doi:10.1097/MCA.0000000000000681
NLM
Lemos SGD, Benvenuti LA, Aiello VD, Nicolau JC, Ribeiro EE, Ribeiro HB. Hydrophilic-coating material guidewire embolization after complex percutaneous coronary intervention: necroscopic findings [Internet]. Coronary artery disease. 2019 ; 30( 2): 152-155.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1097/MCA.0000000000000681
Vancouver
Lemos SGD, Benvenuti LA, Aiello VD, Nicolau JC, Ribeiro EE, Ribeiro HB. Hydrophilic-coating material guidewire embolization after complex percutaneous coronary intervention: necroscopic findings [Internet]. Coronary artery disease. 2019 ; 30( 2): 152-155.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1097/MCA.0000000000000681
Artigo de periodico
Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial (2019)
Franchi, Francesco; James, Stefan K; Lakic, Tatevik Ghukasyan; Budaj, Andrzej J; Cornel, Jan H; Katus, Hugo A; Keltai, Matyas; Kontny, Frederic; Lewis, Basil S; Nicolau, José Carlos
Source: Journal of the american heart association. Unidade: FM
Subjects: DIABETES MELLITUS, INSUFICIÊNCIA RENAL CRÔNICA, SÍNDROME CORONARIANA AGUDA, AGREGAÇÃO PLAQUETÁRIA, ANTICOAGULANTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FRANCHI, Francesco et al. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the american heart association, v. 8, n. 6, 2019Tradução . . Disponível em: https://doi.org/10.1161/JAHA.118.011139. Acesso em: 03 jun. 2024.
APA
Franchi, F., James, S. K., Lakic, T. G., Budaj, A. J., Cornel, J. H., Katus, H. A., et al. (2019). Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the american heart association, 8( 6). doi:10.1161/JAHA.118.011139
NLM
Franchi F, James SK, Lakic TG, Budaj AJ, Cornel JH, Katus HA, Keltai M, Kontny F, Lewis BS, Nicolau JC. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial [Internet]. Journal of the american heart association. 2019 ; 8( 6):[citado 2024 jun. 03 ] Available from: https://doi.org/10.1161/JAHA.118.011139
Vancouver
Franchi F, James SK, Lakic TG, Budaj AJ, Cornel JH, Katus HA, Keltai M, Kontny F, Lewis BS, Nicolau JC. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial [Internet]. Journal of the american heart association. 2019 ; 8( 6):[citado 2024 jun. 03 ] Available from: https://doi.org/10.1161/JAHA.118.011139
Artigo de periodico
Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure (2019)
Ponikowski, Piotr; Kirwan, Bridget-Anne; Anker, Stefan D.; Dorobantu, Maria; Drozdz, Jaroslaw; Fabien, Vincent; Filippatos, Gerasimos; Haboubi, Teba; Keren, Andre; Nicolau, José Carlos
Source: European journal of heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, DOENÇAS NUTRICIONAIS E METABÓLICAS, FERRO, COMPOSTOS INORGÂNICOS, HOSPITALIZAÇÃO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PONIKOWSKI, Piotr et al. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European journal of heart failure, v. 21, n. 12, p. 1651-1658, 2019Tradução . . Disponível em: https://doi.org/10.1002/ejhf.1710. Acesso em: 03 jun. 2024.
APA
Ponikowski, P., Kirwan, B. -A., Anker, S. D., Dorobantu, M., Drozdz, J., Fabien, V., et al. (2019). Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European journal of heart failure, 21( 12), 1651-1658. doi:10.1002/ejhf.1710
NLM
Ponikowski P, Kirwan B-A, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Nicolau JC. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure [Internet]. European journal of heart failure. 2019 ; 21( 12): 1651-1658.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1002/ejhf.1710
Vancouver
Ponikowski P, Kirwan B-A, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Nicolau JC. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure [Internet]. European journal of heart failure. 2019 ; 21( 12): 1651-1658.[citado 2024 jun. 03 ] Available from: https://doi.org/10.1002/ejhf.1710

USP Schools

ReP

Filtros

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Conference titles

Countries/Territories

Funding Agencies

Indexado em

Non normalized affiliation

Countries of institutions of collaboration